P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19
361 Indexadrenoceptor antagonists, combined,226t, 227t
adrenoceptors,201t
α–adrenoceptors, 202
β–adrenoceptors, 202
adrenocorticotropic hormone (ACTH), 259 –260,
354
adrenosteroid hormones, 31
afferent fibres, primary, 135
affinity of drugs, 32 –33
after-potentials, 229
age, drug effects, 22 –23
agonists, 32 –33
full, 33
inverse, 32 –34
mixedαandβ, 211–212
partial, 32 –33
see alsoα 1 -agonists;α 2 -agonists;β-agonists
Alberti regime, 352
albumin,303t
composition,302t
drug binding,7, 303t
liver function tests, 22
alcohol dehydrogenase, 18
aldosterone, 45
aldosterone antagonists, 308 –309
alfentanil, 146
kinetics, 146
lipid solubility, 6
presentation, 146
uses, 146
alkane group, 92
alkanol group, 92
alkyl group, 92
alpha blockersseeα-adrenoceptor antagonists
alteplase, 345
althesin, 90
aluminium-containing antacids, 292
alveolar concentration,116f
alveolar ventilation, 116
amethocaine, topical, 12 –13, 173t, 174t
amide group, 92
amiloride, 308
amine group, 92 –93
amino acids, 86 –88
γ-aminobutyric acidseeGABA
aminoglycosides, 319 –320
kinetics, 320
mechanism of action, 319 –320
side-effects, 320
aminophylline, 212 –214
drug interactions, 213 –214
effects, 213 –214
kinetics, 214
mechanism of action, 213
presentation, 212toxicity, 214
uses, 212
aminosteroids, 90
amiodarone, 239 –240
drug interactions, 240
kinetics, 240
mechanism of action, 239
presentation, 239
side-effects, 239 –240
uses, 239
warfarin interaction, 41
amitriptyline, 274 –276
amoxycillin, 314
cAMP, 28
AMPA receptor, 26
amphoterocin B, 331 –332
ampicillin, 313 –314
amrinone, 216
analgesics, 135 –162
COX-2 inhibitors
preferential,152t, 158–159
specific,152t, 159–162
non-specific COX inhibitors,152t, 153–158
see alsonon-steroidal anti-inflammatory
drugs (NSAIDs); opioids
anaphylactic reactions, thiopentone-induced,
105 –106
angiotensin I, 258
angiotensin I receptor antagonists (ARAs),
261 –262
angiotensin II, 258 –260
angiotensin II receptor antagonists, 259 –260
angiotensin-converting enzyme (ACE), 18 ,
258
angiotensin-converting enzyme (ACE)
inhibitors, 24 , 259–260
angiotensin I receptor antagonist
comparison, 262
antacids, 292
action mechanisms, 24
oral, 8
antagonists, 32 –33
competitive, 35 –37, 42
irreversible, 38
non-competitive, 37
reversible, 35 –37
anti-arrhythmics, 228 –245
digoxin toxicity treatment, 232 –233, 245
supraventricular tachyarrhythmia treatment,
230 –237
Vaughan–Williams classification, 229 , 231t
ventricular tachyarrhythmia
with supraventricular tachyarrhythmias,
239 –245
treatment, 237 –238